Novo Nordisk Initiates Phase II Clinical Trials of GLP-1/GIP Dual Agonist Head-to-Head Against Tirzepatide

Mar 25, 2024 09:35 CST Updated 09:35

Novo Nordisk

Insulin Developer and Manufacturer

｜Edited by the Content Team of Zhong Peptide Biochemical

March 22, 2024DayNovo Nordisk registered the phase II clinical trial of NN0519-0130 for weight loss and blood sugar reduction on the Clinicaltrials.gov website, planning to enroll 343 and 288 patients respectively, with an expected preliminary completion in November 2024.

Both Phase II clinical trials used Tirzepatide as the positive control group.

According to the planned timeline of Novo Nordisk's R&D pipeline, NN0159-0130 is most likely a once-weekly injectable GLP-1R/GIPR dual agonist.

The phase I clinical data of the GLP-1R/GIPR dual-target agonist are as follows: The hypoglycemic dosing regimen is 3mg administered for three weeks, once a week, followed by 6mg administered for one week. The weight loss dosing regimen consists of five escalating doses administered daily, starting from 0.3mg and escalating to 3mg over a total of 15 weeks. After four weeks of hypoglycemic treatment, HbA1c decreased by more than 0.5%, and after 15 weeks of weight loss treatment, body weight decreased by nearly 12%.

Based on the phase I clinical registration information of NNC0519-0130 and the phase II clinical control group being Tirzepatide, it can be basically confirmed that this project is a GLP-1R/GIPR dual-target agonist.

About Diabetes

Diabetes is a chronic disease. It occurs when the pancreas does not produce enough insulin or when the body cannot effectively use the insulin it produces. Insulin is a hormone that regulates blood sugar. Hyperglycemia or elevated blood sugar levels are indicative of diabetes.The common consequences of poor control can, over time, cause serious damage to many systems in the human body (especially nerves and blood vessels).Diabetes can be treated and its consequences avoided or delayed with diet, physical activity, medication, and regular screening and treatment for complications. The number of people with diabetes has risen from 108 million in 1980 to 422 million in 2014. The prevalence is increasing more rapidly in low- and middle-income countries than in high-income countries.

AboutNovo Nordisk

Novo Nordisk, founded in 1923, is a global leading biopharmaceutical company headquartered in Copenhagen, the capital of Denmark. Our goal is to drive change to defeat diabetes and other serious chronic diseases such as obesity, rare blood disorders, and endocrine disorders. To achieve this, we lead scientific breakthroughs, expand the accessibility of our medicines, and are committed to preventing and ultimately curing these diseases. Novo Nordisk has approximately 47,000 employees across 80 countries and regions worldwide and provides products and services to more than 168 countries and regions globally.

Source:

1. Medical Notes

2.News Details (novonordisk.com)